Navigation Links
Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round
Date:3/27/2008

ieris has made remarkable progress in the course of the past year and this financing event enables the Company to further execute its strategy and to leverage the value in its proprietary Anticalin(R) approach."

Notes to editors

About Pieris AG

Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins(R), a novel class of targeted human proteins designed to diagnose and treat serious human disorders. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the Company applies a balanced risk business model to the development of Anticalin product candidates.

About Anticalin(R) Technology

Anticalins(R) are engineered binding proteins derived from the scaffold of natural human lipocalins. Anticalins are selected to have prescribed binding properties with selectivity and affinity fundamentally similar to that of monoclonal antibodies. Being human in origin, Anticalins are predicted to have minimal immunogenicity in man. Furthermore, compared to conventional antibodies Anticalins benefit from their small size (20 kDa), robust physicochemical properties and simple composition that together allow highly soluble and stable products to be manufactured from bacteria. Anticalins are amenable to further engineering to balance their favorable tissue penetration with adjustable serum half life. Moreover, Anticalins have been developed as Duocalins(R), whose dual targeting format allows multiple targets to be bound and modulated through a single molecule.

Pieris exclusively owns the Anticalin patent estate, which offers complete freedom to operate outside the patent boundaries defined by conventional antibody products. Key patents have already been granted both in the US and in Europe.

About PRS-050

PRS-050 Anticalin(R) has been designed to specifically bind and block the signalling activity of vascular endothelial growth factor (VEGF) in cance
'/>"/>

SOURCE Pieris AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
2. Moodys Raises Rating for Gerresheimer
3. SleepQuest Raises Awareness of Sleep Disorders
4. Arthrosurface Raises $4 Million of Preferred Equity Financing
5. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
6. Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
7. Circassia Raises GBP11 Million ($21.8 Million) in Oversubscribed Second Round Funding
8. Primera Biosystems Raises $21 Million in Series B Private Round
9. Cellectar, Inc. Raises $13 Million in Private Offering
10. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
11. Anesiva Raises $45 Million in Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched Sound ... Patients listen to sound therapy that is tailor-made for ... to months, their tinnitus volume decreases. , AudioNotch has previously ... Notched White Noise. Now, AudioNotch is pleased to announce to ...
(Date:1/14/2014)... a leading provider of strategic communications services to corporations and organizations ... the United States and Europe ... is returning to the firm,s Washington, D.C. ... than two years of service as Associate Commissioner for the Office ...
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 iLab ... Michelle Detwiler as the new Director of Product Strategy. In ... as well as iLab sub-teams to guide in the development ... that iLab provides the maximum possible benefit to the scientific ...
(Date:1/14/2014)... (PRWEB) January 13, 2014 Bob Hainsey, ... more than 20 years in the industry, has joined ... . Hainsey will serve as the society’s Science and ... Hainsey join SPIE as our Technology Strategist, further strengthening ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... , , ... /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the ... of cancer, today announced the dosing of the first patient under ... Therapy in prostate cancer patients. The study will evaluate the localization, ...
... 11 Allscripts (Nasdaq: MDRX ) announced today ... centers of the mid-South and the flagship of Vanderbilt University Medical ... ensure continuity of care and improve the efficiency of the hospital patient ... , (Logo: ...
... --, -- Revenue increased 26.4% to $26.1 million, ... than 200 basis points to 10.3%; Adjusted diluted EPS increased ... -- Sales of PurCotton(R) products increased 71.1% to $1.9 Million, ... the first six months in fiscal year 2009, ...
Cached Biology Technology:Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial 2Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial 3Vanderbilt University Hospital Selects Allscripts Care Management 2Vanderbilt University Hospital Selects Allscripts Care Management 3Vanderbilt University Hospital Selects Allscripts Care Management 4Vanderbilt University Hospital Selects Allscripts Care Management 5Vanderbilt University Hospital Selects Allscripts Care Management 6Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 2Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 3Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 4Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 5Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 6Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 7Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 8Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 9Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 10Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 11Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 12Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 13Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 14Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 15Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 16Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 17Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 18Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 19
(Date:4/18/2014)... sprout as soon as they,re planted may be good news ... careful. In the wild, a plant whose seeds sprouted at ... More than just an insurance policy against late frosts or ... long-term advantages too: Plants whose seeds put off sprouting ... finds in a team of researchers working at the National ...
(Date:4/18/2014)... A team of researchers led by a ... selected to receive a $7.5 million Department of Defense ... and basic scientific foundations for the predictable design of ... wide diversity of structures from plants and animals, including ... taking what biological systems have constructed over millions of ...
(Date:4/17/2014)... CHAMPAIGN, Ill. A drug under clinical trials to ... of broad-spectrum drugs that act against various bacteria, fungal ... study by University of Illinois chemists and collaborators. , ... the team determined the different ways the drug SQ109 ... tweaked to target other pathogens from yeast to malaria ...
Breaking Biology News(10 mins):Plants with dormant seeds give rise to more species 2Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3Multitarget TB drug could treat other diseases, evade resistance 2
... celebrates distinguished government scientist Professor Robert (Bob) Watson who ... Chief Scientific Advisor to the Department of Environment, ... alumnus, Professor Watson is recognised for his contributions to ... and global warming. Professor Peter Heathcote, Head of ...
... A Cardiff University researcher has secured a highly sought-after ... stage. Dr Paola Borri, Cardiff School of Biosciences, is ... interface between life and physical sciences Now, she has ... Leadership Award for the next five years. This will support ...
... at Virginia Tech have constructed a mathematical and computational ... simulate the cellular and molecular changes underlying chronic inflammation ... explore different interactions of cells in the immune system, ... the colon, and identify intervention points to perhaps stop ...
Cached Biology News:Honorary Fellowship awarded to government Chief Scientific Advisor 2Boost for world-leading microscopy project 2Math model of colon inflammation singles out dangerous immune cells 2Math model of colon inflammation singles out dangerous immune cells 3
... SBED Protein:Protein Interaction Reagent A powerful ... rapidly gained traction as an in vitro ... number of publications feature the exclusive Pierce ... study a variety of issues relating to ...
... Incubator is a compact benchtop and ... microprocessor controller with a large display ... agitation speed. Air circulation inside to ... Temperature can be easily calibrated from ...
... fast emerging as a powerful new tool ... now, only amino groups have been able ... such as our Sulfo-SBED. Sulfhydryl-reactive Mts-Atf-Biotin and ... additions to the protein interaction tool chest ...
... MULTI-FUN Incubator is a compact benchtop ... a microprocessor controller with a large ... and agitation speed. Air circulation inside ... incubator. Temperature can be easily calibrated ...
Biology Products: